Atlas Trials

Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors

Clinical trial NCT00698841 · COMPLETED

Trial details

NCT number
NCT00698841
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced Cancer
Start date
2009-02-01
Primary completion
2010-02-01
Enrollment
79

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.